This post was originally published on this site A single dose of PolyPEPI1018 — Treos Bio’s investigational off-the-shelf vaccine for colorectal cancer — induced promising immune responses and clinical signs of efficacy when given in combination with standard maintenance therapy in metastatic colorectal cancer patients, interim results from a Phase 1/2 trial show. The findings…
This post was originally published on this site Most prostate cancer patients who choose to undergo active surveillance instead of treatment are not receiving the appropriate disease monitoring, bringing into question whether or not this is a safe treatment option, according to a population-based study. The study, “Population-based cohort of prostate cancer patients on active…
This post was originally published on this site A sentinel node biopsy, used to determine whether cancer has spread to lymph nodes, is a feasible way to obtain information and avoid lymph node dissection in patients with early-stage ovarian cancer, a new study shows. The study, “Sentinel-Node Biopsy in Early Stage Ovarian Cancer: Preliminary Results…
This post was originally published on this site Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from Phase 1/2 trials show. The new findings were presented in two posters, titled “ANCHOR (OP-104): A Phase 1 study update of…
This post was originally published on this site People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Amgen and Allergan’s Kanjinti (trastuzumab-anns), a biosimilar to Genentech’s Herceptin (trastuzumab), for all indications of its reference product — including as a treatment for HER2-positive breast cancer, the companies announced. A biosimilar is a biological medical product that is nearly identical…
This post was originally published on this site A connection discovered between Alzheimer’s and the bacteria that cause gum disease suggests that improved oral hygiene may decrease the risk of developing the disorder, a study reports. The study, “Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors,” was published…
This post was originally published on this site In the United States, 2.1 million men age 65 and older have Alzheimer’s disease. With Father’s Day approaching, we recognize that these numbers represent many dads, though fewer men than women have the disease. Caregiving isn’t gender-specific. Among Americans age 71 and older, 16 percent of women…
This post was originally published on this site The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial (NCT03734692) is expected to treat 45 ovarian cancer patients who responded to platinum-based chemotherapy for at least six months.…
This post was originally published on this site Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and controlled disease in nearly 90% of multiple myeloma patients who had failed multiple prior treatments. The preliminary findings were discussed in an oral…
